植入式胰岛素帮浦市场规模、份额、成长分析（按帮浦类型、储液器容量、输注方式、最终用户、年龄层、适应症、通路和地区划分）－2025-2032年产业预测

2023 年全球植入式胰岛素帮浦市场价值为 322 亿美元，预计从 2024 年的 393.5 亿美元成长到 2032 年的 1956.6 亿美元，在预测期（2025-2032 年）内复合年增长率为 22.2%。

全球植入式胰岛素帮浦市场正经历强劲成长，这主要得益于糖尿病盛行率的不断上升，推动了对先进胰岛素输注系统的需求。患者越来越倾向于持续、精准的胰岛素输注，因为他们希望更好地控制血糖，减少长期併发症。技术进步改进了胰岛素帮浦的设计，使其更加可靠、易于使用。人们对有效糖尿病管理的认识不断提高，加上医疗政策和报销计画的支持，进一步推动了胰岛素帮浦的普及。然而，高昂的成本、手术费用、在发展中地区认可度有限、严格的监管障碍、潜在的感染风险以及持续的设备维护需求等挑战，可能会阻碍市场扩张。总而言之，植入式胰岛素帮浦的发展既面临机会，也面临挑战。

全球植入式胰岛素帮浦市场按帮浦类型、储液器容量、输注方式、最终用户、年龄层、适应症、通路和地区进行细分。按泵类型划分，市场分为可编程植入式泵、闭合迴路泵、开放回路型泵、不可编程植入式泵和其他类型。依储液器容量划分，市场分为小容量（<10 mL）、中容量（10-20 mL）、大容量（>20 mL）及其他类型。依输注方式划分，市场分为持续基础大剂量投药、餐前胰岛素输注、基础-餐前联合输注及其他类型。按最终用户划分，市场分为医院、门诊手术中心 (ASC)、糖尿病专科诊所、居家医疗机构和其他机构。依年龄组别划分，市场分为儿童（<17岁）、成人（18-64岁）及老年人（>65岁）。依适应症划分，市场可分为第1型糖尿病（T1DM）、第2型糖尿病（T2DM）及其他类型。依分销管道划分，市场可分为儿童（17岁以下）、成人（18-64岁）及老年人（65岁以上）。依地区划分，市场可分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。

全球植入式胰岛素帮浦市场驱动因素

全球植入式胰岛素帮浦市场的主要驱动因素之一是糖尿病（尤其是第1型糖尿病）在全球范围内的日益普及。这种激增主要归因于肥胖率上升、久坐的生活方式以及遗传因素。随着糖尿病管理变得愈发重要，人们对能够提供更佳血糖控制和更灵活治疗方案的先进技术的需求也日益增长，从而改善患者的生活品质。植入式胰岛素帮浦因其能够持续输注胰岛素、减少频繁注射的需求以及实现个人化治疗，而备受寻求有效糖尿病管理方案的患者和医疗保健提供者的青睐。

限制全球植入式胰岛素帮浦市场的因素

全球植入式胰岛素帮浦市场面临的主要限制因素之一是设备及其维护的高成本。初始投资和持续费用，包括植入手术、维护和定期更换，对许多患者和医疗机构都难以负担。此外，该技术的复杂性以及患者和医疗专业人员都需要接受专门培训，进一步阻碍了其推广应用。这些经济和后勤方面的挑战可能会疏远潜在用户，并限制市场扩张，尤其是在医疗资金和基础设施薄弱的地区。

全球植入式胰岛素帮浦市场趋势

全球植入式胰岛素帮浦市场正经历一个重大趋势：这些设备与持续血糖监测（CGM）系统的融合。这种融合催生了先进的闭合迴路系统，通常被称为人工胰臟解决方案，它能够根据即时血糖测量值自动调节胰岛素剂量。随着此类智慧整合技术的日益普及，它们将提高治疗的精准度，简化日常糖尿病管理，并增强患者对自身健康的信心。这一趋势凸显了医疗保健解决方案向个人化和自动化方向发展的趋势，从而提高糖尿病管理的效率，并改善患者的整体治疗效果。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 重大投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球植入式胰岛素帮浦市场规模（按帮浦类型和复合年增长率划分）（2025-2032 年）

• 市场概览
• 可程式设计植入式泵
• 闭合迴路泵
• 开放回路泵
• 不可编程植入式泵
• 其他的

全球植入式胰岛素帮浦市场规模（按储液器容量和复合年增长率划分）（2025-2032 年）

• 市场概览
• 小体积（10毫升或更少）
• 中等容量（10-20毫升）
• 大容量（>20毫升）
• 其他的

全球植入式胰岛素帮浦市场规模（按输送方式及复合年增长率划分）（2025-2032 年）

• 市场概览
• 持续基础给药
• 大剂量投药
• 基础-餐时联合治疗
• 其他的

全球植入式胰岛素帮浦市场规模（按最终用户和复合年增长率划分）（2025-2032 年）

• 市场概览
• 医院
• 门诊手术中心（ASC）
• 糖尿病诊所
• 居家照护
• 其他的

全球植入式胰岛素帮浦市场规模（依年龄层划分）及复合年增长率（2025-2032 年）

• 市场概览
• 儿童（17岁以上）
• 成年人（18-64岁）
• 老年人（65岁以上）

全球植入式胰岛素帮浦市场规模（按适应症和复合年增长率划分）（2025-2032 年）

• 市场概览
• 1型糖尿病（T1DM）
• 2型糖尿病（T2DM）
• 其他的

全球植入式胰岛素帮浦市场规模（按分销管道和复合年增长率划分）（2025-2032 年）

• 市场概览
• 儿童（17岁以上）
• 成年人（18-64岁）
• 老年人（65岁以上）

全球植入式胰岛素帮浦市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2024 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2022-2024年营收年比比较

主要企业简介

• Medtronic Plc.（Ireland）
• Insulet Corporation（United States）
• Tandem Diabetes Care, Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Ypsomed AG（Switzerland）
• SOOIL Development Co., Ltd.（South Korea）
• Novo Nordisk（Denmark）
• Johnson & Johnson（United States）
• Bigfoot Biomedical, Inc.（United States）
• Beta Bionics（United States）
• Diabeloop SACA（France）
• Debiotech SA（Switzerland）
• Terumo Corporation（Japan）
• Wuxi Apex Medical Co., Ltd.（China）
• ViCentra BV（Netherlands）
• CeQur（Switzerland）
• Medtrum Technologies Inc.（China）
• MicroPort Scientific（China）
• Menarini Diagnostics Srl（Italy）
• Ascensia Diabetes Care（Switzerland）

结论与建议

Global Implantable Insulin Pump Market size was valued at USD 32.2 billion in 2023 and is poised to grow from USD 39.35 billion in 2024 to USD 195.66 billion by 2032, growing at a CAGR of 22.2% during the forecast period (2025-2032).

The global implantable insulin pump market is experiencing robust growth, driven by the escalating prevalence of diabetes, which fuels demand for advanced insulin delivery systems. Patients increasingly favor continuous and precise insulin management, stemming from a desire for better diabetes control to mitigate long-term complications. Technological advancements have led to enhancements in pump design, improving reliability and user-friendliness. Rising awareness of effective diabetes management, coupled with supportive healthcare policies and reimbursement programs, further promotes adoption. However, challenges such as high costs, surgical expenses, limited awareness in developing regions, stringent regulatory hurdles, potential infection risks, and the necessity for ongoing device maintenance may hinder market expansion. Overall, the landscape presents both opportunities and obstacles for implantable insulin pump growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Implantable Insulin Pump market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Implantable Insulin Pump Market Segments Analysis

Global Implantable Insulin Pump Market is segmented by Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel and region. Based on Pump Type, the market is segmented into Programmable Implantable Pumps, Closed-loop Pumps, Open-loop Pumps, Non-programmable Implantable Pumps and Others. Based on Reservoir Size, the market is segmented into Small Volume (<=10 mL), Medium Volume (10-20 mL), Large Volume (>20 mL) and Others. Based on Delivery Mode, the market is segmented into Continuous Basal Delivery, Bolus Delivery, Combined Basal-Bolus Delivery and Others. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Diabetes Clinics, Homecare Settings and Others. Based on Age Group, the market is segmented into Pediatric (<=17 years), Adults (18-64 years) and Geriatric (>=65 years). Based on Indication, the market is segmented into Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM) and Others. Based on Distribution Channel, the market is segmented into Pediatric (<=17 years), Adults (18-64 years) and Geriatric (>=65 years). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Implantable Insulin Pump Market

One of the key market drivers for the global implantable insulin pump market is the increasing prevalence of diabetes, particularly type 1 diabetes, across the globe. This surge is largely attributed to rising obesity rates, sedentary lifestyles, and genetic factors. As diabetes management becomes more critical, there is a growing demand for advanced technologies that provide better glycemic control, flexibility, and improved quality of life for patients. Implantable insulin pumps offer continuous insulin delivery, reducing the need for frequent needle injections and allowing for personalized therapy, thus appealing to both patients and healthcare providers in their quest for effective diabetes management solutions.

Restraints in the Global Implantable Insulin Pump Market

One significant market restraint for the global implantable insulin pump market is the high cost associated with the devices and their management. The initial investment and ongoing expenses, including surgeries for implantation, maintenance, and the need for regular replacements, can be prohibitive for many patients and healthcare providers. Additionally, the complexity of the technology and the necessity for specialized training for both patients and healthcare professionals further complicate adoption. These financial and logistical challenges may deter potential users and limit market expansion, particularly in regions with less robust healthcare funding and infrastructure.

Market Trends of the Global Implantable Insulin Pump Market

The Global Implantable Insulin Pump market is witnessing a significant trend towards the integration of these devices with Continuous Glucose Monitoring (CGM) systems. This fusion leads to the emergence of advanced closed-loop systems, often described as artificial pancreas solutions, which facilitate automatic insulin delivery adjustments based on real-time glucose readings. As these smart integrations gain traction, they enhance treatment precision, streamline daily diabetes management, and bolster patient assurance in their health regimes. This trend underscores a broader movement towards personalized and automated healthcare solutions, making diabetes management more efficient and improving overall patient outcomes in the process.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Implantable Insulin Pump Market Size by Pump Type & CAGR (2025-2032)

• Market Overview
• Programmable Implantable Pumps
• Closed-loop Pumps
• Open-loop Pumps
• Non-programmable Implantable Pumps
• Others

Global Implantable Insulin Pump Market Size by Reservoir Size & CAGR (2025-2032)

• Market Overview
• Small Volume (<=10 mL)
• Medium Volume (10-20 mL)
• Large Volume (>20 mL)
• Others

Global Implantable Insulin Pump Market Size by Delivery Mode & CAGR (2025-2032)

• Market Overview
• Continuous Basal Delivery
• Bolus Delivery
• Combined Basal-Bolus Delivery
• Others

Global Implantable Insulin Pump Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Diabetes Clinics
• Homecare Settings
• Others

Global Implantable Insulin Pump Market Size by Age Group & CAGR (2025-2032)

• Market Overview
• Pediatric (<=17 years)
• Adults (18-64 years)
• Geriatric (>=65 years)

Global Implantable Insulin Pump Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Type 1 Diabetes Mellitus (T1DM)
• Type 2 Diabetes Mellitus (T2DM)
• Others

Global Implantable Insulin Pump Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Pediatric (<=17 years)
• Adults (18-64 years)
• Geriatric (>=65 years)

Global Implantable Insulin Pump Market Size & CAGR (2025-2032)

• North America (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Pump Type, Reservoir Size, Delivery Mode, End User, Age Group, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Medtronic Plc. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tandem Diabetes Care, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOOIL Development Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bigfoot Biomedical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beta Bionics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diabeloop SACA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Debiotech S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi Apex Medical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViCentra B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CeQur (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtrum Technologies Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort Scientific (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Menarini Diagnostics S.r.l. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascensia Diabetes Care (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations